TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti‐CTLA4 treatment

Immune checkpoint inhibitors (ICIs) have recently changed therapeutic paradigms for patients across multiple cancer types. However, current biomarkers cannot accurately predict responses to ICIs. Telomerase reverse transcriptase (TERT) mutations lead to an aberrant upregulation of TERT expression, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Huahua, Li, Jia, Zhang, Chenyue, Zhang, Chenxing, Wang, Haiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541140/
https://www.ncbi.nlm.nih.gov/pubmed/32810393
http://dx.doi.org/10.1002/cam4.3376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541140/
https://www.ncbi.nlm.nih.gov/pubmed/32810393
http://dx.doi.org/10.1002/cam4.3376

Ejemplares similares